Instituto de Biomedicina y Biotecnología de Cantabria, Department of Physiology and Pharmacology, University of Cantabria, Santander, Spain.
Biol Psychiatry. 2010 Nov 1;68(9):869-72. doi: 10.1016/j.biopsych.2010.07.023. Epub 2010 Sep 22.
Alterations in brain density and signaling associated with monoamine receptors are believed to play a role in depressive disorders. This study evaluates the functional status of α₂(A)-adrenoceptors in postmortem frontal cortex of depressed subjects.
G-protein activation and inhibition of adenylyl cyclase (AC) activity induced by the α₂-adrenoceptor agonist UK14304 were measured in triplicate in samples from 15 suicide victims with an antemortem diagnosis of major depression and 15 matched control subjects.
Basal [³⁵S] guanosine γ thio-phosphate (GTPγS) binding and cyclic adenosine monophosphate accumulation did not differ between groups. In depressed victims, an increase in [³⁵S] GTPγS binding potency (EC₅₀ = .58 μmol/L vs. EC₅₀ = 3.31 μmol/L; p < .01; depressed vs. control) and a significant reduction in the maximal inhibition of AC activity (I(max) = 27 ± 4% vs. I(max) = 47 ± 5%; p < .01) were observed after incubation with the α(2)-adrenoceptor agonist UK14304. No differences were found between antidepressant-free and antidepressant-treated subjects. A significant relationship between EC₅₀ values for [³⁵S] GTPγS and I(max) values for AC assay was found (n = 30; r = -.43; p < .05).
The dual regulation of α(2A)-adrenoceptor signaling pathways raises the possibility that factors affecting the G-protein cycle and/or selective access of Gα(i/o)-protein to AC might be relevant to receptor abnormalities in depression, providing further support for the involvement of α₂(A)-adrenoceptors in the pathogenesis of depression.
与单胺受体相关的脑密度和信号改变被认为在抑郁症中起作用。本研究评估了抑郁症患者死后前额皮质中α₂(A)-肾上腺素能受体的功能状态。
在 15 例有自杀行为且生前被诊断为重度抑郁症的患者和 15 例匹配的对照者的样本中,重复测量了 α₂-肾上腺素受体激动剂 UK14304 诱导的 G 蛋白激活和腺苷酸环化酶(AC)活性的抑制作用。
基础[³⁵S]鸟苷酸γ硫代磷酸(GTPγS)结合和环腺苷酸积累在两组之间无差异。在抑郁症患者中,观察到[³⁵S]GTPγS 结合效力(EC₅₀=0.58 μmol/L 与 EC₅₀=3.31 μmol/L;p<0.01;抑郁症患者与对照组)的增加和 AC 活性最大抑制(I(max)=27±4% 与 I(max)=47±5%;p<0.01)的显著降低,在与 α(2)-肾上腺素受体激动剂 UK14304 孵育后。未发现抗抑郁药物治疗组与未治疗组之间存在差异。发现[³⁵S]GTPγS 的 EC₅₀ 值与 AC 测定的 I(max)值之间存在显著相关性(n=30;r=-.43;p<0.05)。
α(2A)-肾上腺素能受体信号通路的双重调节增加了影响 G 蛋白循环和/或 Gα(i/o)-蛋白选择性进入 AC 的因素与抑郁症中受体异常相关的可能性,为 α₂(A)-肾上腺素能受体参与抑郁症的发病机制提供了进一步的支持。